| Matthew E Sterling, MD | |
|
919 Conestoga Rd Ste 300, Bryn Mawr, PA 19010-1352 | |
| (610) 525-6580 | |
| (610) 525-3664 |
| Full Name | Matthew E Sterling |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 7 Years |
| Location | 919 Conestoga Rd Ste 300, Bryn Mawr, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891056792 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | MD460723 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bryn Mawr Hospital | Bryn mawr, PA | Hospital |
| Paoli Hospital | Paoli, PA | Hospital |
| Main Line Hospital Lankenau | Wynnewood, PA | Hospital |
| Riddle Memorial Hospital | Media, PA | Hospital |
| Chester County Hospital | West chester, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Centers For Advanced Urology, Llp | 3274800941 | 81 |
News Archive
There has been continual progress in expanding immunization programs over time, but even before the COVID-19 pandemic, tens of millions of children worldwide were not receiving basic doses of vaccines.
AstraZeneca today announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca's investigational drug, vandetanib, for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer (MTC).
Researchers at Boston Children's Hospital report that a fatty chemical naturally found in damaged tissues can induce an unexpected kind of immune response, causing immune cells to go into a "hyperactive" state that is highly effective at rallying infection-fighting T-cells. The findings, published online by Science on April 21, could enhance vaccines and make them much more effective.
The Centers for Disease Control and Prevention (CDC) has received permission from the Food and Drug Administration (FDA) to provide intravenous artesunate for emergency use in the United States for persons with severe malaria.
› Verified 3 days ago
| Entity Name | Academic Urology Of Pa, Llc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1336439645 PECOS PAC ID: 3072606607 Enrollment ID: O20110610000032 |
News Archive
There has been continual progress in expanding immunization programs over time, but even before the COVID-19 pandemic, tens of millions of children worldwide were not receiving basic doses of vaccines.
AstraZeneca today announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca's investigational drug, vandetanib, for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer (MTC).
Researchers at Boston Children's Hospital report that a fatty chemical naturally found in damaged tissues can induce an unexpected kind of immune response, causing immune cells to go into a "hyperactive" state that is highly effective at rallying infection-fighting T-cells. The findings, published online by Science on April 21, could enhance vaccines and make them much more effective.
The Centers for Disease Control and Prevention (CDC) has received permission from the Food and Drug Administration (FDA) to provide intravenous artesunate for emergency use in the United States for persons with severe malaria.
› Verified 3 days ago
| Entity Name | Centers For Advanced Urology, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811351083 PECOS PAC ID: 3274800941 Enrollment ID: O20170531000529 |
News Archive
There has been continual progress in expanding immunization programs over time, but even before the COVID-19 pandemic, tens of millions of children worldwide were not receiving basic doses of vaccines.
AstraZeneca today announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca's investigational drug, vandetanib, for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer (MTC).
Researchers at Boston Children's Hospital report that a fatty chemical naturally found in damaged tissues can induce an unexpected kind of immune response, causing immune cells to go into a "hyperactive" state that is highly effective at rallying infection-fighting T-cells. The findings, published online by Science on April 21, could enhance vaccines and make them much more effective.
The Centers for Disease Control and Prevention (CDC) has received permission from the Food and Drug Administration (FDA) to provide intravenous artesunate for emergency use in the United States for persons with severe malaria.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew E Sterling, MD 919 Conestoga Rd Ste 300, Bryn Mawr, PA 19010-1352 Ph: (610) 525-6580 | Matthew E Sterling, MD 919 Conestoga Rd Ste 300, Bryn Mawr, PA 19010-1352 Ph: (610) 525-6580 |
News Archive
There has been continual progress in expanding immunization programs over time, but even before the COVID-19 pandemic, tens of millions of children worldwide were not receiving basic doses of vaccines.
AstraZeneca today announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca's investigational drug, vandetanib, for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer (MTC).
Researchers at Boston Children's Hospital report that a fatty chemical naturally found in damaged tissues can induce an unexpected kind of immune response, causing immune cells to go into a "hyperactive" state that is highly effective at rallying infection-fighting T-cells. The findings, published online by Science on April 21, could enhance vaccines and make them much more effective.
The Centers for Disease Control and Prevention (CDC) has received permission from the Food and Drug Administration (FDA) to provide intravenous artesunate for emergency use in the United States for persons with severe malaria.
› Verified 3 days ago
Dr. Daniel Kim, DO Urology Medicare: Not Enrolled in Medicare Practice Location: 130 S Bryn Mawr Ave, Bryn Mawr, PA 19010 Phone: -- | |
Dr. Mehrdad M Soroush, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 919 Conestoga Rd, Building 1, Suite 300, Bryn Mawr, PA 19010 Phone: 610-565-6580 Fax: 610-525-3664 | |
Pauline Elaine Greene, Urology Medicare: Medicare Enrolled Practice Location: 919 Conestoga Rd Ste 300, Bryn Mawr, PA 19010 Phone: 610-525-6580 Fax: 610-525-3664 | |
Dr. David E Mcginnis, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 919 Conestoga Rd, Building One Suite 300, Bryn Mawr, PA 19010 Phone: 610-525-6580 Fax: 610-525-3664 | |
Zachariah Taylor, DO Urology Medicare: Not Enrolled in Medicare Practice Location: 130 S Bryn Mawr Ave, Bryn Mawr, PA 19010 Phone: 530-925-5626 | |
Dr. Ian Thomas Madison, DO Urology Medicare: Not Enrolled in Medicare Practice Location: 130 S Bryn Mawr Ave, Bryn Mawr, PA 19010 Phone: 484-337-3000 | |
Dr. Leigh S Bergmann, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 919 Conestoga Rd, Building One Suite 300, Bryn Mawr, PA 19010 Phone: 610-525-6580 Fax: 610-525-3664 |